Filtered By:
Drug: Dexamethasone
Vaccination: Covid Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 45 results found since Jan 2013.
Improving COVID-19 Disease Severity Surveillance Measures: Statewide Implementation Experience
Ann Intern Med. 2023 May 16. doi: 10.7326/M23-0618. Online ahead of print.ABSTRACTMeasurement of the burden of COVID-19 on U.S. hospitals has been an important element of the public health response to the pandemic. However, because of variation in testing density and policies, the metric is not standardized across facilities. Two types of burdens exist, one related to the infection control measures that patients who test positive for SARS-CoV-2 require and one from the care of severely ill patients receiving treatment of COVID-19. With rising population immunity from vaccination and infection, as well as the availability o...
Source: Annals of Internal Medicine - May 15, 2023 Category: Internal Medicine Authors: Shira Doron Paul A Monach Catherine M Brown Westyn Branch-Elliman Source Type: research
Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic
DISCUSSION: This survey, based on real-time pharmacological and medical assessment of ADRs and weekly meetings in a specific national committee, made it possible to identify relevant safety signals which contribute to patient care with no delay. The main safety signal highlighted was serious cardiac damage under hydroxychloroquine, alone or combined with azithromycin and also with lopinavir/ritonavir. This signal has contributed to the evolution of the recommendations for these 2 drugs. The methodology of this survey has been taken over and is still going on for the pharmacovigilance monitoring of vaccines against COVID-19...
Source: Therapie - February 8, 2023 Category: Psychiatry & Psychology Authors: Aur élie Grandvuillemin Fanny Rocher Marie Blanche Valnet-Rabier Milou-Daniel Drici Anne Dautriche French Pharmacovigilance Network Source Type: research
Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators
Biochem Pharmacol. 2023 Jan 30:115437. doi: 10.1016/j.bcp.2023.115437. Online ahead of print.ABSTRACTFatal "cytokine storms (CS)" observed in critically ill COVID-19 patients are consequences of dysregulated host immune system and over-exuberant inflammatory response. Acute respiratory distress syndrome (ARDS), multi-system organ failure, and eventual death are distinctive symptoms, attributed to higher morbidity and mortality rates among these patients. Consequent efforts to save critical COVID-19 patients via the usage of several novel therapeutic options are put in force. Strategically, drugs being used in such patients...
Source: Biochemical Pharmacology - February 2, 2023 Category: Drugs & Pharmacology Authors: Nusrath Yasmeen S Harikrishnan Sudarshan S Lakhawat Manali Datta Pushpender K Sharma Ajay Jain Rakhi Khanna S Jayalakshmi Vikram Kumar Source Type: research
TWiV 978: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses co-detections of other respiratory viruses among children hospitalized with COVID-19, preprint review should form part of PhD programs and postdoc training, early and increased Influenza activity among children, COVID-19 vaccines versus pediatric hospitalization, SARS-CoV-2 variant-related abnormalities detected by prenatal MRI, protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the Omicron variant and severe disease, protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe dis...
Source: This Week in Virology - MP3 Edition - January 28, 2023 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
The effectiveness of dexamethasone as a combination therapy for COVID-19
Acta Pharm. 2022 Apr 13;72(3):345-358. doi: 10.2478/acph-2022-0030. Print 2022 Sep 1.ABSTRACTCoronavirus disease 2019 (COVID-19) was reported as a global pandemic in March 2020 after invading many countries and leaving behind tens of thousands of infected patients in a brief time span. Approval of a few vaccines has been obtained and their efficacy of varying degrees established. Still, there is no effective pharmaceutical agent for the treatment of COVID-19 though several drugs are undergoing clinical trials. Recent studies have shown that dexamethasone, a corticosteroid, can reduce the rate of COVID-19-related mortality ...
Source: Acta Pharmaceutica - January 18, 2023 Category: Drugs & Pharmacology Authors: Nader Namazi Source Type: research
Myoclonus status revealing COVID 19 infection
DISCUSSION: Our patient presented with acute isolated multifocal myoclonus status without cognitive impairment. These movements were prominent, spontaneous, worsened by action, and sensitive to touch and sound. The anatomical source of this myoclonus could be cortical or subcortical despite the absence of evident EEG discharges. Several diseases can cause acute myoclonus such as severe hypoxia, metabolic disturbances, and paraneoplastic syndromes. these diagnoses were ruled out in our patient. Post-vaccinal origin was also suggested, but its accountability was not proven. Thus, the two hypothetic etiologies raised were eit...
Source: Herpes - November 29, 2022 Category: Infectious Diseases Authors: Dina Ben Mohamed Rania Zouari Jihen Ketata Fatma Nabli Samir Blel Samia Ben Sassi Source Type: research
The Effect of Dexamethasone Treatment on COVID-19 Prognosis in Cancer Patients
CONCLUSION: Our data showed that dexamethasone therapy protocol affected COVID-19 prognoses in cancer patients, and it is preferable to not discontinue therapy after infection. A rigorous prospective comparison between early and late dexamethasone dosing is needed to determine the best protocol for treatment.PMID:36366306 | DOI:10.3390/vaccines10111798
Source: Cancer Control - November 11, 2022 Category: Cancer & Oncology Authors: Lina Souan Zienab Al-Khairy Maysaa' Adnan Al-Binni Abdelkader Battah Maher A Sughayer Source Type: research
COVID-19: Pathophysiology, transmission, and drug development for therapeutic treatment and vaccination strategies
Curr Pharm Des. 2022 Jul 29. doi: 10.2174/1381612828666220729093340. Online ahead of print.ABSTRACTCOVID-19, a dreaded and highly contagious pandemic, is flagrantly known for its rapid prevalence across the world. Till date, none of the treatments are distinctly accessible for this life-threatening disease. Under the prevailing conditions of medical emergency, one creative strategy for the identification of novel and potential antiviral agents gaining momentum in research institutions and progressively being leveraged by pharmaceutical companies is target-based drug repositioning/repurposing. A continuous monitoring and re...
Source: Current Pharmaceutical Design - August 1, 2022 Category: Drugs & Pharmacology Authors: Vishal Kumar Singh Himani Chaurasia Richa Mishra Ritika Srivastava Aditya K Yadav Jayati Dwivedi Prashant Singh Ramendra K Singh Source Type: research
